UBS AM
XENE icon

UBS AM’s Xenon Pharmaceuticals XENE Stock Holding History

UBS AM’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.6M Sell
374,748
-418
-0.1% -$23.2K ﹤0.01% 884
2026
Q1 		$21.8M Buy
375,166
+374,930
+158,869% +$17.3M ﹤0.01% 849
2025
Q4 		$10.6K Buy
+236
New +$9.91K ﹤0.01% 2844
2025
Q3 		– Sell
-404,384
Closed -$12.7M – 2636
2025
Q2 		$12.7M Buy
404,384
+340,816
+536% +$11.1M ﹤0.01% 1242
2025
Q1 		$2.13M Sell
63,568
-128,284
-67% -$4.87M ﹤0.01% 1965
2024
Q4 		$7.52M Buy
191,852
+29,169
+18% +$1.21M ﹤0.01% 1395
2024
Q3 		$6.4M Buy
162,683
+217
+0.1% +$8.75K ﹤0.01% 1446
2024
Q2 		$6.33M Buy
162,466
+84,982
+110% +$3.4M ﹤0.01% 1364
2024
Q1 		$3.34M Hold
77,484
– – ﹤0.01% 1444
2023
Q4 		$3.57M Buy
77,484
+8,683
+13% +$307K ﹤0.01% 1413
2023
Q3 		$2.35M Buy
68,801
+15,749
+30% +$589K ﹤0.01% 1541
2023
Q2 		$1.9M Hold
53,052
– – ﹤0.01% 1682
2023
Q1 		$1.9M Buy
53,052
+14,114
+36% +$521K ﹤0.01% 1682
2022
Q4 		$1.54M Buy
38,938
+534
+1% +$19.4K ﹤0.01% 1658
2022
Q3 		$1.39M Buy
38,404
+11,496
+43% +$413K ﹤0.01% 1783
2022
Q2 		$819K Sell
26,908
-1,928
-7% -$58.3K ﹤0.01% 2073
2022
Q1 		$882K Buy
28,836
+774
+3% +$23.2K ﹤0.01% 2205
2021
Q4 		$877K Buy
+28,062
New +$839K ﹤0.01% 2278
2021
Q3 		– Sell
-319,090
Closed -$5.94M – 2777
2021
Q2 		$5.94M Sell
319,090
-15,651
-5% -$288K ﹤0.01% 1294
2021
Q1 		$5.99M Sell
334,741
-3,090
-0.9% -$52.4K ﹤0.01% 1268
2020
Q4 		$5.2M Sell
337,831
-30,448
-8% -$356K ﹤0.01% 1279
2020
Q3 		$4.08M Buy
368,279
+3,522
+1% +$41.4K ﹤0.01% 1237
2020
Q2 		$4.57M Buy
+364,757
New +$4.64M ﹤0.01% 1150

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

UBS AM's XENE Position: Q2 2026 in Review

UBS AM reduced its Xenon Pharmaceuticals (XENE) stake by 0.11% in Q2 2026, selling an estimated $23.2K and leaving 374,748 shares worth $22.6M. The position accounts for ﹤0.01% of the portfolio, ranked #884.

UBS AM first reported a position in XENE in Q2 2020 and has held it in 23 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • UBS AM held 374,748 shares of Xenon Pharmaceuticals worth $22.6M as of Q2 2026.
  • UBS AM sold 418 Xenon Pharmaceuticals shares in Q2 2026, an estimated $23.2K.
  • Xenon Pharmaceuticals made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #884 holding.
  • UBS AM first reported a position in Xenon Pharmaceuticals in Q2 2020 and has held it in 23 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.